FORM OF PURCHASE AGREEMENT



 Exhibit 4.1 
  

PURCHASE AGREEMENT 
  
 dated as of March 15, 2005 
  
 by and between 
  
 INSMED INCORPORATED 
  
 and 
  
 [NAME OF
PURCHASER] 
  

  
 5.5% SENIOR CONVERTIBLE NOTE DUE 2008-2010 
  
 and 
  
 COMMON STOCK PURCHASE WARRANT 
  









 INSMED INCORPORATED 
  
 PURCHASE AGREEMENT 
  
 5.5% SENIOR CONVERTIBLE NOTE DUE 2008-2010 
  
 and 
  
 COMMON STOCK PURCHASE WARRANT 
  
 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page


	 1.
	  	 Definitions
	  	1
	 2.
	  	 Purchases and Sales of the Note and Warrant
	  	5
	 2.1
	  	 Purchase and Sale
	  	5
	 2.2
	  	 Closing
	  	6
	 3.
	  	 Representations and Warranties of the Company
	  	6
	 3.1
	  	 Organization, Good Standing and Qualification
	  	6
	 3.2
	  	 Authorization
	  	6
	 3.3
	  	 Capitalization
	  	6
	 3.4
	  	 Valid Issuance, Enforceable Obligation
	  	7
	 3.5
	  	 Consents
	  	7
	 3.6
	  	 Delivery of SEC Filings; Business; Non-Public Information
	  	7
	 3.7
	  	 Use of Proceeds
	  	8
	 3.8
	  	 No Material Adverse Change
	  	8
	 3.9
	  	 Registration Statements
	  	9
	 3.10
	  	 Form S-3 Eligibility
	  	9
	 3.11
	  	 No Conflict, Breach, Violation or Default
	  	9
	 3.12
	  	 Tax Matters
	  	10
	 3.13
	  	 Title to Properties
	  	10
	 3.14
	  	 Certificates, Licenses, Authorizations and Permits
	  	10
	 3.15
	  	 No Labor Disputes
	  	11
	 3.16
	  	 Intellectual Property
	  	11
	 3.17
	  	 Environmental Matters
	  	11
	 3.18
	  	 Litigation
	  	12
	 3.19
	  	 Financial Statements
	  	12
	 3.20
	  	 Insurance Coverage
	  	12
	 3.21
	  	 Compliance with Nasdaq Continued Listing Requirements
	  	12
	 3.22
	  	 Acknowledgement of Potential Dilution
	  	12
	 3.23
	  	 Brokers and Finders
	  	13
	 3.24
	  	 No Directed Selling Efforts or General Solicitation
	  	13
	 3.25
	  	 Private Offering
	  	13
	 3.26
	  	 Internal Accounting Controls
	  	13

  

 - i - 









					
	 3.27
	  	 Sarbanes-Oxley Act
	  	13
	 3.28
	  	 Disclosures
	  	14
	 3.29
	  	 Rights Agreement
	  	14
	 4.
	  	 Representations and Warranties of the Purchaser
	  	14
	 4.1
	  	 Purchase Entirely for Own Account
	  	14
	 4.2
	  	 Investment Experience
	  	14
	 4.3
	  	 Disclosure of Information
	  	14
	 4.4
	  	 Restricted Securities
	  	15
	 4.5
	  	 Investor Status
	  	15
	 4.6
	  	 No General Solicitation
	  	15
	 4.7
	  	 Residency of Purchaser
	  	15
	 4.8
	  	 Brokers and Finders
	  	15
	 4.9
	  	 Authorization
	  	15
	 4.10
	  	 Risk Factors
	  	15
	 4.11
	  	 Reliance
	  	15
	 4.12
	  	 Absence of Certain Transactions
	  	16
	 4.13
	  	 Survival
	  	16
	 5.
	  	 Registration Rights Agreement
	  	16
	 6.
	  	 Certain Covenants of the Company and the Purchaser
	  	16
	 6.1
	  	 Rule 144
	  	16
	 6.2
	  	 Limitation on Certain Transactions
	  	16
	 6.3
	  	 Right of the Purchasers to Participate in Future Transactions
	  	17
	 6.4
	  	 Reports and Information
	  	20
	 6.5
	  	 Press Releases
	  	21
	 6.6
	  	 No Conflicting Agreements
	  	21
	 6.7
	  	 Insurance
	  	21
	 6.8
	  	 Compliance with Laws
	  	21
	 6.9
	  	 Listing of Underlying Shares and Warrant Shares and Related Matters
	  	21
	 6.10
	  	 Form 8-K
	  	21
	 6.11
	  	 Legends
	  	22
	 6.12
	  	 Limitation on Certain Actions
	  	23
	 6.13
	  	 Reasonable Best Efforts
	  	23
	 6.14
	  	 Debt Obligation
	  	23
	 6.15
	  	 Limitation on Material Non-Public Information
	  	23
	 7.
	  	 Conditions to Closing
	  	24
	 7.1
	  	 Conditions to the Company’s Obligations to Issue and Sell
	  	24
	 7.2
	  	 Conditions to the Purchaser’s Obligations to Purchase
	  	24
	 8.
	  	 Miscellaneous
	  	25
	 8.1
	  	 Successors and Assigns
	  	25
	 8.2
	  	 Counterparts
	  	26
	 8.3
	  	 Titles and Subtitles
	  	26
	 8.4
	  	 Notices
	  	26
	 8.5
	  	 Expenses
	  	26
	 8.6
	  	 Amendments and Waivers
	  	27

  

 - ii - 









					
	 8.7
	  	 Severability
	  	27
	 8.8
	  	 Entire Agreement
	  	27
	 8.9
	  	 Further Assurances
	  	28
	 8.10
	  	 Applicable Law
	  	28
	 8.11
	  	 Remedies
	  	28
	 8.12
	  	 Jurisdiction
	  	28
	 8.13
	  	 Survival
	  	28
	 8.14
	  	 Construction; Purchaser Status
	  	29
	 8.15
	  	 Acknowledgment
	  	29
	 8.16
	  	 Certain Waivers
	  	29

  
 EXHIBITS 
  

	
	 Exhibit A – Form of Note

	 Exhibit B – Form of Warrant

	 Exhibit C – Form of Registration Rights Agreement

	 Exhibit D – Form of Opinion of Goodwin Procter LLP to Be Delivered on Closing Date

	 Exhibit E – Form of Opinion of Woods Rogers PLC to Be Delivered on Closing Date

	 Exhibit F – Form of Press Release


  
 SCHEDULES 
  

			
	 Schedule 3.3
	  	Capitalization

  

 - iii - 








 PURCHASE AGREEMENT 
  
 THIS PURCHASE AGREEMENT, dated as of March 15, 2005 (this “Agreement”), by and between INSMED
INCORPORATED, a Virginia corporation (the “Company”), and [NAME OF PURCHASER] (the “Purchaser”). 
  
 W I T N E S S E T H: 
  
 WHEREAS, the Purchaser wishes to purchase from the Company, and the
Company wishes to sell and issue to the Purchaser, upon the terms and subject to the conditions of this Agreement, for the Purchase Price (i) a Note (such capitalized term and all other capitalized terms used herein having the respective meanings
provided herein) in principal amount set forth on the signature pages hereto and (ii) a Warrant initially entitling the holder to purchase the number of shares of Common Stock set forth on the signature pages hereto; and 
  
 WHEREAS, at or before the Closing, the parties hereto are executing
and delivering, one to the other, the Registration Rights Agreement, pursuant to which, among other things, the Company will agree to provide certain registration rights under the 1933 Act, and the rules and regulations promulgated thereunder, and
applicable state securities laws for the resale of the shares of Common Stock issuable upon conversion of, or otherwise issued in exchange for or respect of, the Note and issuable upon exercise of the Warrant; 
  
 NOW THEREFORE, in consideration of the premises and the mutual
covenants made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. Definitions. 
  
 1.1 As used in this Agreement, the terms “Agreement”, “Company” and “Purchaser” shall have the respective meanings assigned
to such terms in the introductory paragraph of this Agreement. 
  
 1.2 All the agreements or instruments herein defined shall mean such agreements or instruments as the same may from time to time be supplemented or amended or the terms thereof waived or modified to the extent permitted by, and in
accordance with, the terms thereof and of this Agreement. 
  
 1.3
The following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined): 
  
 “Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with the subject Person. For purposes of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under common control with”), as used with


  









 
respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of
such Person, whether through the ownership of voting securities or by contract or otherwise. 
  
 “AMEX” means the American Stock Exchange, Inc. 
  
 “Approved Markets” means Nasdaq, the NYSE and the AMEX. 
  
 “Board of Directors” means the Board of Directors of the Company. 
  
 “Business Day” means any day other than a Saturday, Sunday or a day on which commercial banks in The City of New
York are authorized or required by law or executive order to remain closed. 
  
 “Closing” means the closing of the purchase and sale of the Note and Warrant on the Closing Date. 
  
 “Closing Date” means 10:00 a.m., New York City time, the date that is one Business Days after the date this Agreement is executed and delivered
by the parties hereto, or such other time or date as mutually agreed by the parties hereto. 
  
 “Closing Location” means the offices of Goodwin Procter LLP, 599 Lexington Avenue, New York, New York. 
  
 “Common Stock” means the Common Stock, $0.01 par value, of the Company. 
  
 “Common Stock Equivalent” means any warrant, option, subscription or purchase right with respect to shares of
Common Stock, any security convertible into, exchangeable for, or otherwise entitling the holder thereof to acquire, shares of Common Stock or any warrant, option, subscription or purchase right with respect to any such convertible, exchangeable or
other security. 
  
 “Encumbrances” means all mortgages,
deeds of trust, claims, security interests, liens, pledges, leases, subleases, charges, escrows, options, proxies, rights of occupancy, rights of first refusal, preemptive rights, covenants, conditional limitations, hypothecations, prior
assignments, easements, title retention agreements, indentures, security agreements or any other encumbrances of any kind. 
  
 “Environmental Laws” shall have the meaning provided in Section 3.17. 
  
 “Event of Default” shall have the meaning to be provided or provided in the Note. 
  
 “Excluded Shares” shall have the meaning provided in Section
6.3(b). 
  

 - 2 - 








 “Generally Accepted Accounting Principles” means, for any Person, the United States generally
accepted accounting principles and practices applied by such Person from time to time in the preparation of its audited financial statements. 
  
 “Intellectual Property” means all franchises, patents, trademarks, service marks, tradenames (whether registered or unregistered), copyrights,
corporate names, licenses, trade secrets, proprietary software or hardware, proprietary technology, technical information, discoveries, designs and other proprietary rights, whether or not patentable, and confidential information (including, without
limitation, know-how, processes and technology) used in the conduct of the business of the Company or any Subsidiary, or in which the Company or any Subsidiary has an interest. 
  
 “Majority Holders” shall have the meaning to be provided or provided in the Note. 
  
 “Margin Stock” shall have the meaning provided in Regulation U of
the Board of Governors of the Federal Reserve System (12 C.F.R. Part 221). 
  
 “Material Adverse Effect” means a material adverse effect on (i) the business, properties, operations, condition (financial or other) results of operations or financial prospects of the Company and the
Subsidiaries, taken as a whole; (ii) the validity or enforceability of, or the ability of the Company to perform its obligations under, the Transaction Documents; or (iii) the rights and remedies of the Purchaser under the terms of the Transaction
Documents. 
  
 “1934 Act” means the Securities Exchange
Act of 1934, as amended, and the rules and regulations of the SEC promulgated thereunder. 
  
 “1933 Act” means the Securities Act of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder. 
  
 “Nasdaq” means the Nasdaq National Market or the Nasdaq Small Cap Market. 
  
 “Note” means the 5.5% Senior Convertible Note due 2008-2010 in the
principal amount set forth on the signature page hereto and in the form attached as Exhibit A issuable or issued by the Company. 
  
 “NYSE” means the New York Stock Exchange, Inc. 
  

“Offering” means the offering that is the subject of this Agreement. 
  
 “Optional Redemption Price” shall have the meaning provided in the Note. 
  
 “Other Notes” means the 5.5% Senior Convertible Notes due 2008-2010
issued by the Company pursuant to the Other Purchase Agreements. 
  

 - 3 - 








 “Other Purchase Agreements” means the several Purchase Agreements, dated as of the date hereof,
between the Company and the purchasers parties thereto pursuant to which the Company is issuing other 5.5% Senior Convertible Notes due 2008-2010 and Common Stock Purchase Warrants. 
  
 “Person” means an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 
  
 “Preferred Share Purchase Rights” means the Preferred Share
Purchase Rights issued or issuable pursuant to the Rights Agreement (or any similar rights hereafter issued by the Company with respect to the Common Stock). 
  
 “Principal Market” shall have the meaning to be provided or provided in the Note. 
  
 “Pro Rata Share” means with respect to each capital raising transaction to which Section 6.3 applies an amount
equal to the product obtained by multiplying (x) an amount equal to all of the securities being issued in such capital raising transaction times (y) a fraction of which the numerator is the total number of shares of Common Stock which would
then be issuable upon conversion of the Note and upon exercise of the Warrant for cash (in each case determined without regard to any limitation on conversion or exercise thereof) and the denominator is the total number of shares of issued and
outstanding Common Stock calculated on a fully diluted basis to include the total number of shares of Common Stock that could be issued upon the exercise or conversion of all outstanding Common Stock Equivalents. 
  
 “Purchase Price” means the amount shown on the signature pages to
this Agreement as the Purchaser’s Purchase Price. 
  
 “Purchaser Share Notice” shall have the meaning provided in Section 6.11. 
  
 “Purchasers” shall mean the Purchaser of the Securities under this Agreement and the Purchasers purchasing securities under the Other Purchase Agreements. 
  
 “Registration Rights Agreement” means the Registration Rights
Agreement by and between the Company and the Purchaser in the form attached as Exhibit C. 
  
 “Registration Statement” shall have the meaning provided in the Registration Rights Agreement. 
  
 “Regulation D” means Regulation D adopted by the SEC under the 1933
Act. 
  
 “Repurchase Event” shall have the meaning to be
provided or provided in the Note. 
  

 - 4 - 








 “Restricted Ownership Percentage” shall have the meaning provided in Section 6.3(b).

  
 “Rights Agreement” mean the Rights Agreement, dated
as of May 16, 2001, between the Company and First Union National Bank, as Rights Agent. 
  
 “SEC” means the U.S. Securities and Exchange Commission. 
  
 “SEC Filings” means the 2003 10-K and all other reports filed by the Company pursuant to Section 13 or 15(d) of the 1934 Act since December 31,
2003 and on or before the date of this Agreement.  
  
 “Securities” means the Note, the Underlying Shares, the Warrant and the Warrant Shares. 
  
 “Subsidiary” means any corporation or other entity of which a majority of the capital stock or other ownership interests having ordinary voting
power to elect a majority of the board of directors or other persons performing similar functions are at the time directly or indirectly owned by the Company. 
  

“Trading Day” shall have the meaning to be provided or provided in the Note. 
  
 “Transaction Documents” means this Agreement, the Registration Rights Agreement, the Note and the Warrant.

  
 “2003 10-K” means the Company’s Annual Report
on Form 10-K for the year ended December 31, 2003, as filed as the SEC, as amended to the date of this Agreement. 
  
 “Underlying Shares” means the shares of Common Stock and the related Preferred Share Purchase Rights issued or issuable upon conversion of the
Note. 
  
 “Warrant” means the Company’s Common
Stock Purchase Warrant in the amount of shares of Common Stock set forth on the signature page and in the form attached as Exhibit B issuable or issued by the Company. 
  
 “Warrant Shares” means the shares of Common Stock and the related Preferred Share Purchase Rights issuable or
issued upon exercise of or otherwise pursuant to the Warrant. 
  
 2. Purchases and Sales of the Note and Warrant. 
  
 2.1 Purchase and Sale. Upon the terms and subject to the conditions of this Agreement, the Purchaser hereby agrees to purchase from the Company, and the Company hereby agrees to sell to the Purchaser, on the Closing Date, the
Note and the Warrant for the Purchase Price. The Closing shall be held at the Closing Location. The Purchase Price shall be allocated between the Note and the Warrant as may be agreed by the Company and the Purchaser. 
  

 - 5 - 








 2.2 Closing. (a) On the Closing Date, upon the terms and subject to the conditions provided
in this Agreement, the Company shall deliver or cause to be delivered to the Purchaser the following: 
  
 (1) the Note, duly executed by the Company, registered in the name of the Purchaser, and 
  
 (2) the Warrant, duly executed by the Company, registered in the name of the Purchaser. 
  
 (b) At the Closing, upon the terms and subject to the conditions
provided in this Agreement, the Purchaser shall deliver or cause to be delivered to the Company an amount equal to the Purchase Price, by wire transfer of immediately available funds to such account as shall be specified by the Company to the
Purchaser prior to the Closing Date. 
  
 3. Representations
and Warranties of the Company. The Company hereby represents and warrants to, and covenants and agrees with, the Purchaser that: 
  
 3.1 Organization, Good Standing and Qualification. The Company and each Subsidiary is a corporation duly incorporated, validly existing and
subsisting and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties. The Company and each Subsidiary is duly
qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or licensing necessary unless the failure to so
qualify could not be reasonably likely to have a Material Adverse Effect. The Company has no Subsidiaries other than those listed in Exhibit 21.1 to the 2003 10-K and has no investment in any other Person except such investments as would be
classified as current assets on a balance sheet of the Company, prepared in accordance with Generally Accepted Accounting Principles. 
  
 3.2 Authorization. The Company has full corporate power and authority, and all requisite action on the part of the Company, its officers,
directors and stockholders has been taken that is, necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) authorization of the performance of all obligations of the Company under the Transaction Documents, and
(iii) the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their
terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 
  
 3.3 Capitalization. Set forth on Schedule 3.3 hereto is (a) the authorized capital stock of the Company
on the date hereof; (b) the number of shares of capital stock issued and outstanding on the date hereof; (c) the number of shares of capital stock issuable pursuant to the Company’s stock option, stock purchase, stock award and similar plans;
and (d) the number of shares of capital stock issuable and reserved for issuance pursuant to all Common Stock 

  

 - 6 - 








 
Equivalents outstanding or which the Company has agreed to issue (other than the Note, the Other Notes, the Warrant and the Warrants issuable pursuant to the
Other Purchase Agreements). All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable. Except as set forth in Section 6.3 of this Agreement and the
Other Purchase Agreements and except as set forth on Schedule 3.3 hereto, no Person is entitled to preemptive or similar statutory or contractual rights with respect to any securities of the Company. Except as set forth on Schedule 3.3
or in the SEC filings, there are no outstanding Common Stock Equivalents or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any Common Stock Equivalents or other equity securities
of any kind, and except as contemplated by this Agreement and the Other Purchase Agreements, the Company has no plans or proposals, and is not currently in negotiations, for the issuance of any Common Stock Equivalents or capital stock of any kind.
The Company has no knowledge of any voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among any of the security holders of the Company relating to the securities of the Company held
by them. Except as set forth on Schedule 3.3, except in connection with the Other Purchase Agreements and except for registration rights relating to registration statements on file with the SEC as of the date of this Agreement, the Company
has not granted any Person the right (which is now outstanding or effective) to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the
Company for its own account or for the account of any other Person. 
  
 3.4 Valid Issuance, Enforceable Obligation. The Company does not have any obligation to issue shares of Common Stock for which it has not reserved the number of shares of Common Stock it may obligated to issue. The Company has
duly reserved a sufficient number of shares of Common Stock for issuance upon conversion of the Notes and the Other Notes and upon exercise of the Warrants and the Warrants issuable pursuant to the Other Purchase Agreements. The Note and the Warrant
are duly authorized by all necessary actions, corporate or otherwise, on the part of the Company; the Underlying Shares and the Warrant Shares have been duly authorized and when issued in accordance herewith and with the terms of the Note and the
Warrant will be validly issued, fully paid, non-assessable and free and clear of all restrictions, except for restrictions on transfer imposed by applicable securities laws; and the Note and the Warrant, when issued in accordance with this
Agreement, will be free and clear of all restrictions, except for restrictions on transfer imposed by applicable securities laws and the requirements for transfer set forth in this Agreement and the other Transaction Documents. 
  
 3.5 Consents. The execution, delivery and performance by the
Company of the Transaction Documents and the offer, issuance and sale of the Securities do not require the consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been
or will be made pursuant to applicable state securities laws and the requirements of the Nasdaq and other than the filing of a Form D by the Company with the SEC, each of which the Company undertakes to file within the applicable time periods.

  
 3.6 Delivery of SEC Filings; Business; Non-Public
Information. The Company has timely filed all material reports and other documents required to be filed with the SEC pursuant to the 1934 Act for the past twelve months preceding the date hereof. At their 

  

 - 7 - 








 
respective times of filing with the SEC (or if amended or suspended by a filing prior to the date of the Agreement, then on the date of such filing, the SEC
Filings complied in all material respects with the requirements of the 1934 Act and did not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of
the circumstances under which they were made, not misleading, in any such case that has not been corrected in a subsequent filing by the Company with the SEC under the 1934 Act made prior to the date of this Agreement. The Company and the
Subsidiaries are engaged only in the business described in the SEC Filings, and the SEC Filings contain a complete and accurate description of the business of the Company and the Subsidiaries in all material respects. The Company has not provided to
any Purchaser any information required to be filed or disclosed under the 1934 Act that has not been so filed or disclosed. 
  
 3.7 Use of Proceeds. The proceeds of the sale of the Note and the Warrant hereunder and of the exercise of the Warrant shall be used by the
Company for working capital and general corporate purposes. None of such proceeds will be used, directly or indirectly (A) to make any loan to or investment in any other Person or (B) for the purpose, whether immediate, incidental or ultimate, of
purchasing or carrying any Margin Stock or for the purpose of maintaining, reducing or retiring any indebtedness which was originally incurred to purchase or carry any stock that is currently a Margin Stock or for any other purpose which might
constitute the transactions contemplated by this Agreement a “purpose credit” within the meaning of such Regulation U of the Board of Governors of the Federal Reserve System; and neither the Company nor any agent acting on its behalf has
taken or will take any action which might cause this Agreement or the transactions contemplated hereby to violate Regulation T, Regulation U or any other regulation of the Board of Governors of the Federal Reserve System or to violate the 1934 Act,
in each case as in effect now or as the same may hereafter be in effect. 
  
 3.8 No Material Adverse Change. Since the filing of the 2003 Form 10-K with the SEC, and except as otherwise identified and described in the SEC Filings subsequently filed by the Company with the SEC
pursuant to the 1934 Act, there has not been: 
  
 (i) any material change in the consolidated assets, liabilities, financial condition or operating results of the Company and the Subsidiaries from that reflected in the financial statements included in the 2003 10-K, except changes in the
ordinary course of business which have not had, in the aggregate, a Material Adverse Effect; 
  
 (ii) any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the
Company, or any redemption or repurchase of any securities of the Company or any Subsidiary; 
  
 (iii) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company or any
Subsidiary; 
  
 (iv) any waiver by the Company or
any Subsidiary of a material right or of a material debt owed to it which waiver is adverse to the Company or any Subsidiary; 
  

 - 8 - 








 (v) any satisfaction or discharge of any Encumbrance or payment of any obligation by the
Company or any Subsidiary, except in the ordinary course of business and which is not material to the assets, properties, prospects, financial condition, operating results or business of the Company and the Subsidiaries taken as a whole (as such
business is presently conducted and the Company has publicly disclosed it is proposed to be conducted); 
  
 (vi) any material change or amendment to a material contract or arrangement by which the Company or any Subsidiary or any of their
respective assets or properties is bound or subject; 
  
 (vii) any material labor difficulties or labor union organizing activities with respect to employees of or contract workers for the Company or any Subsidiary; 
  
 (viii) any material transaction entered into by the Company or any Subsidiary other than in the ordinary
course of business; or 
  
 (ix) any other event
or condition of any character that would be reasonably likely to have a Material Adverse Effect. 
  
 3.9 Registration Statements. During the preceding two years, each registration statement and any amendment thereto filed by the Company
pursuant to the 1933 Act, as of the date such registration statement or amendment became effective, complied as to form in all material respects with the 1933 Act, and did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading; and each prospectus or supplement filed pursuant to Rule 424 under the
1933 Act, as of its issue date and as of the closing of any sale of securities pursuant thereto did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements made therein, in the light of the circumstances under which they were made, not misleading. 
  
 3.10 Form S-3 Eligibility. The Company is currently eligible to register the resale of its Common Stock in a secondary offering on a
registration statement on Form S-3 under the 1933 Act, and the Company shall maintain such eligibility at least until the Registration Statement is ordered effective by the SEC. 
  
 3.11 No Conflict, Breach, Violation or Default. (a) The execution, delivery and performance of the Transaction
Documents by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under, or result in the creation or imposition of any lien,
charge, security interest or encumbrance under (i) the Company’s Certificate of Incorporation (including any articles of amendment or articles designating series of shares) or the Company’s Bylaws, (ii) any statute, rule, regulation or
order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or any Subsidiary or any of their respective assets or properties, or (iii) any agreement or instrument to which the Company or any
Subsidiary is a party or by which the Company or any Subsidiary is bound or to which 

  

 - 9 - 








 
any of the properties of the Company or any Subsidiary is subject, except for conflicts, breaches, violations, defaults or the creation or imposition of any
lien, charge, security interest or encumbrance that has not had or would not reasonably be expected to have a Material Adverse Effect. 
  
 (b) The Company and each Subsidiary (i) is not in violation of any statute, rule or regulation applicable to the Company or any Subsidiary or its assets,
(ii) is not in violation of any judgment, order or decree applicable to the Company or any Subsidiary or any of their respective assets, and (iii) is not in breach or violation of any agreement, note or instrument to which it or its assets are a
party or are bound or subject, except for breaches or violations which, individually or in aggregate, could not reasonably be likely to have a Material Adverse Effect. Except as described in the SEC Filings, to the best of the Company’s
knowledge, neither the Company nor any Subsidiary has received notice from any Person of any claim or investigation that, if adversely determined, would render the representations or warranties in the preceding sentence untrue or incomplete.

  
 3.12 Tax Matters. The Company and the
Subsidiaries have timely prepared and filed all tax returns required to have been filed by the Company with all appropriate governmental agencies and timely paid all taxes owed by them, except for taxes which it reasonably disputes in good faith or
where failure to make such payment would not reasonably be expected to have a Material Adverse Effect. The charges, accruals and reserves on the books of the Company and the Subsidiaries in respect of taxes for all fiscal periods are adequate in all
material respects, and there are no unpaid assessments against the Company or any Subsidiary nor, to the knowledge of the Company, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any
foreign, U.S. federal, state, or local taxing authority, except such as would not reasonably be expected to result in a Material Adverse Effect. All taxes and other assessments and levies that the Company or any Subsidiary is required to withhold or
to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due, except such as would not reasonably be expected to result in a Material Adverse Effect. There are no tax liens or claims
pending or, to the Company’s knowledge, threatened against the Company or any Subsidiary or any of their respective assets or property which if adversely decided, would have a Material Adverse Effect. 
  
 3.13 Title to Properties. Except as disclosed in the SEC
Filings, the Company and each Subsidiary has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from Encumbrances and defects that would reasonably be expected to have a Material
Adverse Effect on the Company; and except as disclosed in the SEC Filings, the Company and each Subsidiary holds any leased real or personal property under valid and enforceable leases with no exceptions that would reasonably be expected to have a
Material Adverse Effect on the Company. 
  
 3.14
Certificates, Licenses, Authorizations and Permits. The Company and each Subsidiary possesses adequate certificates, licenses, authorizations or permits issued by appropriate governmental agencies or bodies necessary to conduct the business
now operated by it except for those which, if not possessed by the Company or such Subsidiary, individually or in the aggregate would not be reasonably likely to have a Material Adverse Effect, and has not 

  

 - 10 - 








 
received any notice of proceedings relating to the revocation or modification of any such certificate, license, authorization or permit that, if determined
adversely to the Company or any Subsidiary, would individually or in the aggregate be reasonably likely to have a Material Adverse Effect. 
  
 3.15 No Labor Disputes. Except such disputes as would not reasonably be expected to result in a Material Adverse Effect, no labor dispute
with the employees of or contract workers for the Company or any Subsidiary exists or, to the knowledge of the Company, is imminent. 
  
 3.16 Intellectual Property. Except as would not reasonably be expected to result in a Material Adverse Effect, (1) the Company and each
Subsidiary owns or possesses sufficient rights to use all Intellectual Property described or referred to in the Company’s filings pursuant to the 1934 Act as owned or possessed by the Company or that are necessary for the conduct of the
business as now conducted or proposed to be conducted; (2) the use of the Intellectual Property by the Company or any Subsidiary does not, to the knowledge of the Company, violate or infringe on the rights of any other Person; (3) neither the
Company nor any Subsidiary has received any written notice of any conflict between the asserted rights of others and the Company or any Subsidiary with respect to any Intellectual Property; (4) the Company and each Subsidiary has used its
commercially reasonable best efforts to protect its rights in and to all Intellectual Property used by it in its business or in which it has an interest; (5) the Company and each Subsidiary are in compliance with all material terms and conditions of
its agreements relating to the Intellectual Property; (6) neither the Company nor any Subsidiary is, or since December 31, 2001 has been, a defendant in any action, suit, investigation or proceeding relating to infringement or misappropriation by
the Company or any Subsidiary of any Intellectual Property nor has the Company or any Subsidiary been notified of any alleged claim of infringement or misappropriation by the Company or any Subsidiary of any Intellectual Property; (7) to the
knowledge of the Company, none of the products or services the Company and the Subsidiaries are researching, developing, propose to research and develop, make, have made, use, or sell, infringes or misappropriates any Intellectual Property right of
any third party; (8) none of the trademarks and service marks used by the Company or any Subsidiary, to the knowledge of the Company, infringes the trademark or service mark rights of any third party; and (9) to the Company’s knowledge none of
the processes and formulae, research and development results and other know-how relating to the Company’s or the Subsidiaries’ respective businesses, the value of which to the Company or any Subsidiary is contingent upon maintenance of the
confidentiality thereof, has been disclosed to any Person other than Persons bound by written confidentiality agreements. 
  
 3.17 Environmental Matters. Neither the Company nor any Subsidiary is in violation of any statute, rule, regulation, decision or order of
any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic
substances (collectively, “Environmental Laws”), owns or operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any
Environmental Laws, or is subject to any claim relating to any Environmental Laws, except for any such violation, ownership or 

  

 - 11 - 








 
operation of contaminated property, liability or claim that would individually or in the aggregate not be reasonably likely to have a Material Adverse
Effect; and neither the Company nor any Subsidiary is aware of any pending investigation that might lead to such a claim. 
  
 3.18 Litigation. Except as described in the SEC Filings, there are no pending actions, suits or proceedings against the Company or any
Subsidiary or any of their respective properties that, if determined adversely to the Company or such Subsidiary, would individually or in the aggregate have a Material Adverse Effect, or which could otherwise have a material adverse affect on the
validity or enforceability of, or the ability or authority of the Company to perform its obligations under the Transaction Documents; and to the Company’s knowledge, no such actions, suits or proceedings are threatened or contemplated.

  
 3.19 Financial Statements. The consolidated
financial statements included in each SEC Filing present fairly in all material respects the consolidated financial position of the Company and the Subsidiaries as of the dates reported and the consolidated results of operations, changes in
stockholders’ equity and cash flows for the periods reported, all in conformity with Generally Accepted Accounting Principles applied on a consistent basis and in conformity with the rules and regulations of the SEC under the 1934 Act
applicable to the Company, subject, in the case of unaudited financial statements, to (1) normal recurring year-end adjustments, all of which that are necessary for a fair presentation of such financial statements have been included, and (2) the
absence of all required notes thereto. Except as set forth in the consolidated financial statements of the Company included in the SEC Filings filed prior to the date hereof, neither the Company nor any Subsidiary has any liabilities, contingent or
otherwise, except those which individually or in the aggregate are not material to the financial condition or operating results of the Company and the Subsidiaries, taken as a whole. Generally Accepted Accounting Principles are applied on a
“consistent basis” when such principles applied in a current period are comparable in all material respects to those accounting principles applied in a preceding period. 
  
 3.20 Insurance Coverage. The Company and each Subsidiary maintains in full force and effect insurance coverage
which the Company believes to be customary for comparably situated companies. 
  
 3.21 Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq continued listing requirements, except where failure to comply would not result in
de-listing from or the imposition of restrictions or limitations by Nasdaq, and is in good standing on such market. There are no proceedings pending or to the Company’s knowledge threatened against the Company relating to the continued listing
of the Company’s Common Stock on Nasdaq and the Company has not received any notice of, nor to the knowledge of the Company is there any basis for, the suspension of trading of the Common Stock on, or delisting of the Common Stock from, Nasdaq.

  
 3.22 Acknowledgement of Potential Dilution. The
Company understands that the number of shares of Common Stock issuable pursuant to the Note, the Warrant, the Other Notes and the other securities issuable pursuant to the Other Purchase Agreements may be substantial and that such issuance may have
a dilutive effect on the Company’s equity capitalization. 
  

 - 12 - 








 3.23 Brokers and Finders. The Purchaser shall have no liability or responsibility for the
payment of any commission or finder’s fee to any third party in connection with or resulting from this Agreement or the transactions contemplated by this Agreement by reason of any agreement of or action taken by the Company. 
  
 3.24 No Directed Selling Efforts or General Solicitation.
Notwithstanding anything contained on any schedule hereto, neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer
or sale of any of the Securities. 
  
 3.25 Private
Offering. Assuming the correctness of the representations and warranties of the Purchasers set forth in Section 4 of the Purchase Agreements, the offer and sale of Notes and the Warrants hereunder is and, upon conversion of the Notes or
exercise of the Warrants, the issuance of the Underlying Shares will be exempt from registration under the Securities Act. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would (1) adversely affect reliance by the Company on Section 4(2) of the 1933 Act and Regulation D for the exemption from registration under
the 1933 Act for the transactions contemplated hereby or would require registration of the offer and sale of the Note, the Warrant, the Underlying Shares or the Warrant Shares to the Purchaser under the 1933 Act; or (2) require the integration of
the offering of the Securities with any other offering of securities for purposes of determining the need to obtain stockholder approval of the transactions contemplated hereby under the rules of Nasdaq. 
  
 3.26 Internal Accounting Controls. The Company and each of its
Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with Generally Accepted Accounting Principles and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in
accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with
respect to any difference. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including, without limitation, controls and procedures designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Company’s management, including its principal executive officer or officers and its principal
financial officer or officers, as appropriate, to allow timely decisions regarding required disclosure. 
  
 3.27 Sarbanes-Oxley Act. The Company is in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002
that are effective as of the 

  

 - 13 - 








 
date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof. 
  
 3.28 Disclosures. For purposes of this Agreement and the
transactions contemplated hereby, none of the representations or warranties made by the Company under the Transaction Documents, and no written information furnished by the Company pursuant hereto, or in any other document, certificate or written
statement furnished at the Closing by the Company to the Purchaser or any authorized representative of the Purchaser, pursuant to the Transaction Documents or in connection therewith, contains any untrue statement of a material fact or omits to
state a material fact necessary in order to make the statements contained herein and therein, in light of the circumstances under which they were made, not misleading. 
  
 3.29 Rights Agreement. Assuming the correctness of the representations of the Purchasers in Section 4.14 of
this Agreement and the Other Purchaser Agreements, the execution and delivery of this Agreement by the Company, the issuance of the Securities as contemplated by the Transaction Documents and the other transactions contemplated by the Transaction
Documents will not result in any of the Purchasers becoming an “Acquiring Person,” as defined in the Rights Agreement; and the holders of the Note and the Warrants will be entitled, with respect to the Underlying Shares and the Warrant
Shares, and the holders of the Underlying Shares and the Warrant Shares will be entitled, in each case to the benefits available to the holders of Common Stock under the Rights Agreement. 
  
 3.30 Other Purchase Agreements. Each of the Other Purchase Agreements is identical to this Purchase Agreement
except to the extent that information particular to the Purchaser has been included therein and that in one particular of such agreements the Company has agreed to pay the legal fees of counsel for one purchaser, Alexandra Global Master Fund Ltd.,
in connection with the negotiation of the Transaction Documents and the term sheet related thereto. 
  
 4. Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that: 
  
 4.1 Purchase Entirely for Own Account. The Securities to be
acquired by the Purchaser pursuant to this Agreement will be acquired for the Purchaser’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of applicable securities laws,
and the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of applicable securities laws. 
  
 4.2 Investment Experience. The Purchaser acknowledges that it can bear the economic risk and complete loss of
its investment in the Securities and has such knowledge of and experience with securities and financial or business matters that it is capable of fending for itself and evaluating the merits and risks of the purchase of the Note and Warrant and any
conversion or exercise thereof into Underlying Shares or Warrant Shares. 
  
 4.3 Disclosure of Information. The Purchaser has had an opportunity to receive documents related to the Company and to ask questions of and receive answers from the 

  

 - 14 - 








 
Company regarding the terms and conditions of the offering of the Securities; provided however, that neither such inquiries nor any other
investigation conducted by the Purchaser shall modify, amend, limit or otherwise affect the Purchaser’s right to rely on the Company’s representations and warranties contained in the Transaction Documents or made pursuant to the
Transaction Documents. 
  
 4.4 Restricted
Securities. The Purchaser understands that the Note, the Warrant and the Underlying Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company
in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. 
  
 4.5 Investor Status. The Purchaser an “accredited
investor” as defined in Rule 501 of Regulation D or a “QIB” as defined in Rule 144A of the under the 1933 Act. 
  
 4.6 No General Solicitation. The Purchaser did not learn of the offering of the Note and Warrant through any public advertising or general
solicitation (as these terms are used in Regulation D). 
  
 4.7 Residency of Purchaser. The Purchaser is a resident of the state or other jurisdiction indicated below the Purchaser’s name on the signature pages to this Agreement. 
  
 4.8 Brokers and Finders. The Company shall have no liability or
responsibility for the payment of any commission or finder’s fee to any third party in connection with or resulting from this Agreement or the transactions contemplated by this Agreement by reason of any agreement of the Purchaser; and the
Purchaser has not engaged any such broker or finder in connection with the negotiation, execution and delivery of this Agreement. 
  
 4.9 Authorization. The Purchaser has full requisite power and authority and has taken all requisite action on the part of the Purchaser, its
partners, officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents and (ii) authorization of the performance of all obligations of the Purchaser under the Transaction Documents.
The Transaction Documents constitute the legal, valid and binding obligations of the Purchaser, enforceable against the Purchaser in accordance with their terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of
general applicability, relating to or affecting creditors’ rights generally. 
  
 4.10 Risk Factors. Without limiting any other representations and warranties under this Agreement, the Purchaser acknowledges that the Purchaser has reviewed and is aware of the risk factors described in
the SEC Filings. 
  
 4.11 Reliance. Without limiting
any other representations and warranties under this Agreement, the Purchaser has consulted its own financial, legal and tax advisors with respect to the economic, legal and tax consequences of an investment in the Note and Warrant and has 

  

 - 15 - 








 
not relied on the SEC Filings or the Company, its officers, directors or professional advisors or any purchaser of Other Notes as to such consequences.

  
 4.12 Absence of Certain Transactions. From the
date the Purchaser first learned of the offering of the Notes and Warrants to the day prior to execution and delivery of this Agreement, the Purchaser has not made any short sales of the Common Stock. 
  
 4.13 Survival. The Purchaser acknowledges that the
representations, warranties and agreements made by the Purchaser herein shall survive the execution and delivery of this Agreement and the purchase of the Note and Warrant. 
  
 4.14 Rights Agreement. Except as otherwise disclosed to the Company in writing by the Purchaser and
based upon the number of outstanding shares of Common Stock of the Company set forth in Schedule 3.3, the Purchaser, following the purchase of the Securities, shall not, together with all affiliates and associates of such Person, be the
beneficial owner (within the meaning of Rule 13d-3 of 1934 Act) of 15% or more of the Common Stock. 
  
 5. Registration Rights Agreement. The Company acknowledges and agrees that the Company’s execution and delivery of, and full
performance of its obligations under, the Registration Rights Agreement is a material inducement to the Purchaser to execute and deliver this Agreement and purchase and pay for the Note and Warrant. The Company agrees to execute and deliver to the
Purchaser the Registration Rights Agreement at or before the Closing. 
  
 6. Certain Covenants of the Company and the Purchaser. 
  
 6.1 Rule 144. The Company acknowledges that, for purposes of determining the holding period under Rule 144 for Underlying Shares issued upon conversion of the Note, the holding period of such Underlying
Shares shall be tacked to the holding period of the Note and for purposes of determining the holding period under Rule 144 for Warrant Shares issued in a “net” or “cashless” exercise of the Warrant, the holding period of such
Warrant Shares may be tacked to the holding period of the Warrant. The Company agrees not to take a position contrary thereto unless the SEC or its staff by rule or interpretation changes its rules and interpretations thereof in effect on the date
of this Agreement or such rules or interpretations are held invalid or incorrect by a court of competent jurisdiction. 
  
 6.2 Limitation on Certain Transactions. 
  
 (a) Beginning as of the date of this Agreement and until the effective date of the Registration Statement as contemplated by the Registration Rights
Agreement, without the prior written consent of the Purchaser (which consent may be withheld in the Purchaser’s sole discretion), the Company shall not issue or sell or agree to issue or sell any securities in a capital raising transaction,
unless such securities will not be, and are not, registered for sale or resale under the 1933 Act until on or after the effective date of the Registration Statement, provided that the limitation of this Section 6.2(a) shall not apply to securities
issued pursuant to the Company’s duly adopted employee or director bona fide share and option plans or pursuant to 

  

 - 16 - 








 
exercise or conversion of Common Stock Equivalents that are outstanding on the date of this Agreement. 
  
 (b) The Company shall not make an offering of its equity or debt securities,
other than any offering under the 1933 Act that constitutes a public offering that is exempt from the requirement for stockholder approval under Rule 4350(i) of Nasdaq, if such offering will be integrated with the Offering for purposes of Rule
4350(i) of Nasdaq rules and thereby constitute a sale of Common Stock, or Common Stock Equivalents convertible or exercisable, at a price less than the greater of book value or market value for purposes of Rule 4350(i), unless prior to issuance of
such securities the Company shall have obtained stockholder approval therefor that meets the requirements of Rule 4350(i). 
  
 (c) If the Company fails to comply with Section 6.2(b), then, in addition to any other rights and remedies of the Purchaser, at the election of the
Purchaser, the Company shall redeem within five days after such election all, or such portion as specified in writing to the Company by such Purchaser, of the Note for 120% of the Optional Redemption Price and otherwise as if such redemption were
made under Section 2(b) of the Note. 
  
 6.3 Right of the
Purchasers to Participate in Future Transactions. 
  
 (a) Right to Participate. The Purchaser will have a right to participate, on the terms and conditions set forth in this Section 6.3, in all sales by the Company of any (i) shares of Common Stock, (ii) any other equity security
of the Company, including without limitation, preferred shares, (iii) any debt security of the Company which by its terms is convertible into or exchangeable for any equity security of the Company, (iv) any security of the Company that is a
combination of debt and equity, or (v) any option, warrant or other right to subscribe for, purchase or otherwise acquire any such equity security or any such debt security of the Company, in a capital raising transaction that occur within one year
after the Closing Date, other than any such sale that is a public offering underwritten on a firm commitment basis and registered with the SEC under the 1933 Act; provided, however, that if the only Persons eligible to purchase securities in
a particular such transaction are “accredited investors,” as defined in Regulation D, or “QIBs”, as defined in Rule 144A under the 1933 Act, as the case may be, then the Purchaser must be an accredited investor or QIB, as the
case may be, in order to purchase securities in such transactions. Subject to Section 6.15, for any such transaction during such period, the Company shall give five Business Days advance written notice to the Purchaser prior to any offer or sale of
any of the Company’s securities in such transaction by providing to the Purchaser a term sheet which (1) contains all significant business terms of such proposed transaction, (2) is sufficiently detailed so as to reasonably permit the Purchaser
the opportunity to determine whether or not to exercise its rights under this Section 6.3 and (3) is at least as detailed as the term sheet or summary of such transaction as the Company shall furnish to any offeree or broker in such transaction.
Unless the Purchaser shall have refused to receive such term sheet pursuant to Section 6.15, the Purchaser shall have the right to participate in such proposed transaction and to purchase its Pro Rata Share of such securities which are the subject
of such proposed transaction for the same consideration and on the same terms and conditions as contemplated for sales to third parties in such transaction (or such lesser portion thereof as specified by the Purchaser). If the Purchaser elects to
exercise its rights hereunder it must 

  

 - 17 - 








 
deliver written notice to the Company within three Business Days following receipt from the Company of the notice and term sheet meeting the requirements of
this Section 6.3, which notice from the Purchaser shall be conditional upon (1) the Purchaser’s receipt of satisfactory definitive documents for such transaction from the Company if the Company has not furnished final definitive documents for
such transaction to the Purchaser at or before the time the Company gives such notice of such transaction to the Purchaser, and (2) the satisfaction of the other conditions precedent to the obligations of purchasers generally in such transaction to
complete such transaction. If, subsequent to the Company giving notice to the Purchaser hereunder but prior to the Purchaser exercising its right to participate (or the expiration of the three Business Day period without response from the Purchaser
or the rejection of such offer for such financing by the Purchaser), the terms and conditions of the proposed sales to third parties in such transaction are changed from those disclosed in the term sheet provided to the Purchaser, the Company shall
be required to provide a new notice and term sheet meeting the requirements of this Section 6.3, reflecting such revised terms, to the Purchaser hereunder and the Purchaser shall have the right, which must be exercised within three Business Days of
such new notice and such revised term sheet, to exercise its rights to purchase the securities on such changed terms and conditions and otherwise as provided hereunder. If the Purchaser does not exercise its rights hereunder with respect to a
proposed transaction within the period or periods provided, or affirmatively declines to engage in such proposed transaction with the Company, then the Company may proceed with such proposed transaction on the same terms and conditions as noticed to
the Purchaser (assuming the Purchaser has consented to the transaction, if required, pursuant to Section 6.2(a) and such transaction does not violate any other term or provision of the Transaction Documents) with the Purchaser if it has elected to
participate in such proposed transaction, provided that if such proposed transaction is not consummated within 75 days following the Company’s notice hereunder, then the rights hereunder shall again be afforded to the Purchaser for such
proposed transaction. The rights and obligations of this Section 6.3 shall in no way limit or restrict the other rights of the Purchaser pursuant to this Section 6. 
  
 (b) Limitation on Right of First Refusal. Notwithstanding anything to the contrary contained herein, the
number of shares of Common Stock that may be acquired directly or through acquisition of Common Stock Equivalents by the Purchaser pursuant to any transaction to which this Section 6.3 applies shall not exceed a number that, when added to the total
number of shares of Common Stock deemed beneficially owned by the Purchaser (other than by virtue of the ownership of securities or rights to acquire securities (including the Note and the Warrant) that have limitations on the Purchaser’s right
to convert, exercise or purchase similar to the limitation set forth herein (the “Excluded Shares”)), together with all shares of Common Stock deemed beneficially owned at such time (other than by virtue of ownership of Excluded Shares) by
Persons whose beneficial ownership of Common Stock would be aggregated with the beneficial ownership of the Purchaser for purposes of determining whether a group exists or for purposes of determining the Purchaser’s beneficial ownership in
either case for purposes of Section 13(d) of the 1934 Act and Regulation 13D-G thereunder, would result in beneficial ownership by the Purchaser or such group of more than 9.9% of the shares of the Company’s Common Stock (the “Restricted
Ownership Percentage”), computed in accordance with Regulation 13D-G. The Purchaser shall have the right at any time and from time to time to reduce its Restricted Ownership Percentage immediately upon notice to the Company in the event and
only to the extent that Section 16 of the 1934 Act or the rules promulgated thereunder 

  

 - 18 - 








 
(or any successor statute or rules) is changed to reduce the beneficial ownership percentage threshold thereunder from 10%. If the Purchaser is unable by
reason of the Restricted Ownership Percentage to acquire the full amount of securities which the Purchaser would otherwise be entitled to acquire pursuant to this Section 6.3 then (1) the Company shall include in the terms of the securities which
the Purchaser is entitled to purchase under this Section 6.3 a provision comparable to Section 6(h) of the Note and (2) if, notwithstanding the inclusion of the provision required by the immediately preceding clause (1), the Purchaser remains unable
to acquire the full amount of securities which the Purchaser would otherwise be entitled to acquire under this Section 6.3, and thereafter, at any time until the date that is 90 days after the latest closing of the sale of securities in such
transaction by the Company to Persons other than (x) the Purchaser and (y) any Person who is entitled to purchase securities in such transaction pursuant to Section 6.3 of the Other Purchase Agreements, the Purchaser could acquire such securities
without exceeding its Restricted Ownership Percentage, then the Purchaser shall be entitled to acquire such securities at such time; provided, that nothing contained in the immediately preceding clause (2) shall be deemed to permit the
Purchaser to acquire such securities to the extent that such acquisition by the Purchaser would require the Company to obtain stockholder approval pursuant to the rules of the national securities exchange on which the common stock is then listed.
The Company will provide notice to the Purchaser of the date of such latest closing of the sale of securities in such transaction within five Business Days after such closing. 
  
 (c) Right Applicable to Successive Transactions. The rights of the Purchaser under this Section 6.3 shall
apply to all capital raising transactions described in Section 6.3(a) that occur during the period specified in Section 6.3(a). 
  
 (d) Right Inapplicable to Certain Issuances. The issuances of the following securities shall not be considered capital raising transactions
and shall not be subject to the rights of the Purchaser described in Section 6.3(a): 
  
 (1) the issuance by the Company of shares of Common Stock pro rata to all holders of the Common Stock; 
  
 (2) the issuance by the Company of the Notes or the Other
Warrants or shares of Common Stock upon conversion of the Notes or upon exercise of this Warrant or the Other Warrants, in each such case in accordance with the terms of thereof; 
  
 (3) the issuance by the Company of Common Stock upon grant or exercise of options for employees, directors
and consultants under the Company’s 2000 Stock Purchase Plan, the Company’s 2000 Stock Incentive Plan or any other employee benefit plan approved by the Board of Directors after the Closing Date, or the issuance by the Company of shares of
Common Stock to former employees in satisfaction of severance obligations if such issuance has been approved by the Board of Directors; 
  
 (4) the issuance by the Company of Common Stock or Common Stock Equivalents to parties that are suppliers, customers or strategic partners
investing in connection with a commercial relationship with the Company, the primary purpose of which issuance is not to raise capital; 
  

 - 19 - 








 (5) the issuance by the Company of Common Stock or Common Stock Equivalents to the lessor
or vendor in any office lease or equipment lease or similar equipment financing transaction in which the Company or any Subsidiary obtains the use of such office space or equipment for its business; and 
  
 (6) the issuance by the Company of Common Stock upon
conversion or exercise of Common Stock Equivalents outstanding on the Closing Date if the amount of such shares so issuable is disclosed in this Agreement (or the Schedules hereto) or the SEC Filings, in accordance with the terms of such Common
Stock Equivalents in effect on the Closing Date. 
  
 6.4
Reports and Information. For so long as the Purchaser beneficially owns any of the Securities, the Company will furnish to the Purchaser the following reports and information, each of which shall be provided to the Purchaser by e-mail (at
such address as specified in writing by the Purchaser for such purpose) or reputable overnight courier: 
  
 (a) Quarterly Financial Information. In the absence of a Quarterly Report on Form 10-Q filed with the SEC for any of the Company’s
first three fiscal quarters in any fiscal year, within five days after the due date determined without regard to any permitted extensions) for filing such report with the SEC for such fiscal quarter consolidated balance sheets of the Company as at
the end of each of the Company’s first three fiscal quarters and the related consolidated statements of operations, stockholders’ equity and cash flows for such period and for the portion of the Company’s fiscal year ended on the last
day of such quarter, all in reasonable detail and certified by the principal financial officer of the Company to have been prepared in accordance with Generally Accepted Accounting Principles consistently applied, subject to (1) normal recurring
year-end adjustments, all of which that are necessary for a fair presentation of such financial statements shall be included in such financial statements, and (2) the absence of all required notes. 
  
 (b) Annual Financial Information. In the absence of an Annual
Report on Form 10-K timely filed with the SEC for a particular fiscal year, within 15 days after the due date (determined without regard to any permitted extensions) for filing such report with the SEC for such fiscal year a consolidated balance
sheet of the Company as at the end of each fiscal year and the related consolidated statements of earnings, stockholders’ equity and cash flows for such year, prepared in accordance with Generally Accepted Accounting Principles, consistently
applied, and accompanied by the report on such consolidated financial statements of the Company’s independent certified public accountant. 
  
 (c) Other Information. Such other information relating to the Company and the Subsidiaries as from time to time may reasonably be requested
by the Purchaser provided the Company or its Subsidiary has such information available to it in the ordinary course of its business, and further provided that the Company, solely in its own discretion, determines that such information is not
confidential in nature and disclosure to the Purchaser would not be harmful to the Company or its Subsidiary or violate applicable law. 
  

 - 20 - 








 (d) Rule 144. The Company agrees to make publicly available on a timely basis the
information required by Rule 144(c) under the 1933 Act. 
  
 6.5 Press Releases. The Company shall, contemporaneously with the Closing on the Closing Date or as promptly as possible thereafter on the Closing Date, issue a press release, in the form of Exhibit F hereto, concerning
the transactions contemplated hereby. The Company’s other press releases and other public information, to the extent any such press release specifically references the Purchaser, shall contain such information as reasonably requested by the
Purchaser and be reasonably approved by the Purchaser prior to issuance. 
  
 6.6 No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the obligations to the
Purchaser under the Transaction Documents. 
  
 6.7
Insurance. For so long as the Purchaser beneficially owns any of the Securities, the Company shall, and shall cause each Subsidiary to, have in full force and effect (a) insurance that the Company believes to be customary for companies
comparably situated to the Company. 
  
 6.8 Compliance with
Laws. So long as the Purchaser beneficially owns any Securities, the Company will use reasonable efforts to comply with all applicable laws, rules, regulations, orders and decrees of all governmental authorities, except to the extent
non-compliance (in one instance or in the aggregate) could not be reasonably likely to have a Material Adverse Effect. 
  
 6.9 Listing of Underlying Shares and Warrant Shares and Related Matters. The Company agrees to obtain the listing of the Underlying Shares
and Warrant Shares on Nasdaq and, to the extent necessary, to take such action to cause the Underlying Shares and the Warrant Shares to continue to be listed on the Nasdaq. The Company agrees that if the Company applies to have its Common Stock or
other securities traded on any other principal stock exchange or market, it will include in such application the Underlying Shares and Warrant Shares and will take such other action as is necessary to cause such Common Stock to be so listed. For so
long as any of the Note or the Warrant remains outstanding and for a period of at least 30 days immediately thereafter, the Company will take all actions necessary to continue the listing and trading of its Common Stock on at least one of the
Approved Markets, and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such exchange or market, as applicable, to ensure the continued eligibility for trading of the Common
Stock thereon. 
  
 6.10 Form 8- K. Within four
Business Days after the Closing Date, the Company will publicly report the issue and sale of the Note and Warrant and the securities issued pursuant to the Other Purchase Agreements by filing with the SEC a Current Report on Form 8-K under the 1934
Act which report shall describe the material terms and include copies of the Transaction Documents as exhibits to such report. 
  

 - 21 - 








 6.11 Legends. Until registered for resale pursuant to the Registration Rights Agreement or,
in the absence of such registration, until sales under Rule 144(k) under the 1933 Act are permitted, certificates evidencing the Underlying Shares and the Warrant Shares may bear the following legend: 
  
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER
OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER OR HYPOTHECATION IS IN COMPLIANCE THEREWITH. 
  
 and such legend as may be required by the authorities of any state in connection with the qualification of the Underlying Shares and the Warrant Shares for sale, or exemption therefrom, in such state. Upon
registration for resale pursuant to the Registration Rights Agreement or, in the absence of such registration, upon Rule 144(k) under the 1933 Act becoming available, the Company shall promptly (but in no event later than five Business Days after
surrender of the legended certificates to the Company) cause certificates evidencing the Underlying Shares and Warrant Shares previously issued to be replaced with certificates which do not bear the restrictive legends specified above in this
Section 6.11, and all Underlying Shares and Warrant Shares subsequently issued shall not bear the restrictive legend specified above in this Section 6.11. If the Purchaser notifies the Company that, within three Business Days after surrender of such
legended certificates, the Purchaser has not received such certificates without such restrictive legends (each, a “Purchaser Share Notice”), and the Purchaser does not receive such certificates without such restrictive legends within two
Business Days after giving a particular Purchaser Share Notice, then the Company shall pay partial liquidated damages to the Purchaser in cash on demand, calculated at the rate of 1% per month of the original Purchase Price of the Note in respect of
which such Underlying Shares are issuable or issued, and the purchase price paid upon exercise of the Warrant in respect of which such Warrant shares are issuable or issued, and in any such case for which the certificates have not been provided in
compliance with the above, for each day so long as the Company fails to provide such certificates. Notwithstanding the foregoing the Company shall not be liable to the Purchaser for such partial liquidated damages to the extent the failure of the
Company to deliver or to cause to be delivered the unlegended securities results from fire, flood, storm, earthquake, shipwreck, strike, war, acts of terrorism, crash involving facilities of a common carrier, acts of God, or any similar event
outside the control of the Company (it being understood that the action or failure to act of the Company’s Transfer Agent shall not be deemed an event outside the control of the Company except to the extent resulting from fire, flood, storm,
earthquake, shipwreck, strike, war, acts of terrorism, crash involving facilities of a common carrier, acts of God, or any similar event outside the control of such Transfer Agent or the bankruptcy, liquidation or reorganization of such Transfer
Agent under any bankruptcy, insolvency or other similar law). The Purchaser agrees that any sale by the Purchaser of Underlying Shares and Warrant Shares pursuant to the Registration Statement shall be sold in a manner described under the caption
“Plan of Distribution” in such Registration Statement and (A) if such sale is made through a broker, the Purchaser shall instruct such broker to deliver the Prospectus to the purchaser or purchasers (or the broker or brokers therefore) in
connection with such sale, shall supply copies of the 

  

 - 22 - 








 
Prospectus to such broker or brokers and shall instruct such broker or brokers to deliver such Prospectus to the purchaser in such sale or such
purchaser’s broker, (B) if such sale is made in a transaction directly with a purchaser and not through the facilities of any securities exchange or market, the Purchaser shall deliver, or cause to be delivered, the Prospectus to such
purchaser; and (C) if such sale is made by any means other than those described in the immediately preceding clauses (A) and (B), the Purchaser shall otherwise comply with the prospectus delivery requirements of the 1933 Act applicable to such sale.
The Purchaser acknowledges that the removal of the restrictive legends from certificates representing Underlying Shares and Warrant Shares as provided in this Section 6.11 is predicated upon the Company’s reliance on the Purchaser’s
compliance with its covenants in this Section 6.11. 
  
 6.12
Limitation on Certain Actions. From the date of execution and delivery of this Agreement by the parties hereto to the date of issuance of the Note, the Company (1) shall comply with Section 4 of the Note as if the Note were outstanding, (2)
shall not take any action which, if the Note were outstanding, (A) would constitute an Event of Default or, with the giving of notice or the passage of time or both, would constitute an Event of Default or (B) would constitute a Repurchase Event or,
with the giving of notice or the passage of time or both, would constitute a Repurchase Event. 
  
 6.13 Reasonable Best Efforts. Each of the parties shall use its reasonable best efforts timely to satisfy each of the conditions to the other party’s obligations to sell and purchase the Note and
Warrant set forth in Section 7.1 or 7.2, as the case may be, of this Agreement on or before the Closing Date. 
  
 6.14 Debt Obligation. So long as any portion of the Note is outstanding, the Company shall cause its books and records to reflect the
Note as a debt of the Company in its unpaid principal amount, shall cause its financial statements to reflect the Note as a debt of the Company in such amount as shall be the greatest amount permitted in accordance with Generally Accepted Accounting
Principles and as a valid senior debt obligation of the Company for money borrowed. 
  
 6.15 Limitation on Material Non-Public Information. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not disclose material nonpublic information to the
Purchaser, or to advisors to or representatives of the Purchaser, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Purchaser, such advisors and
representatives with the opportunity to accept or refuse to accept such material nonpublic information for review. The Company may, as a condition to disclosing any material nonpublic information hereunder, require the Purchaser’s advisors and
representatives to enter into a confidentiality agreement (including an acknowledgement by such advisors and representatives as to their legal obligations regarding trading in Common Stock during such period of time as they are in possession of
material nonpublic information) in form reasonably satisfactory to the Company and the Purchaser. 
  

 - 23 - 








 7. Conditions to Closing. 
  
 7.1 Conditions to the Company’s Obligations to Issue and Sell. The Company’s obligation to issue and
sell the Note and the Warrant to the Purchaser is conditioned upon satisfaction of the following conditions precedent on the Closing Date (any or all of which may be waived by the Company in its sole discretion): 
  
 (a) The closings under the Other Purchase Agreements shall have occurred;

  
 (b) No legal action, suit or proceeding shall be pending or
threatened which seeks to restrain or prohibit the transactions contemplated by this Agreement; and 
  
 (c) The representations and warranties of the Purchaser contained in this Agreement shall have been true and correct on the date of this Agreement and the
representations and warranties of the Purchaser contained in the Transaction Documents shall be true and correct on the Closing Date as if given on and as of the Closing Date (except for representations given as of a specific date, which
representations shall be true and correct as of such date), and on or before the Closing Date the Purchaser shall have performed all covenants and agreements of the Purchaser contained herein or in any of the other Transaction Documents required to
be performed by the Purchaser on or before the Closing Date. 
  
 7.2 Conditions to the Purchaser’s Obligations to Purchase. The Purchaser’s obligation to purchase the Note and Warrant is conditioned upon satisfaction of the following conditions precedent on the Closing Date (any
or all of which may be waived by the Purchaser in its sole discretion): 
  
 (a) The closings under the Other Purchase Agreements shall have occurred; 
  
 (b) No legal action, suit or proceeding shall be pending or threatened which seeks to restrain or prohibit the transactions contemplated by this Agreement; 
  
 (c) The representations and warranties of the Company contained in this Agreement shall have been true and correct on the
date of this Agreement and the representations and warranties of the Company contained in the Transaction Documents shall be true and correct on the Closing Date as if given on and as of the Closing Date (except for representations given as of a
specific date, which representations shall be true and correct as of such date), and on or before the Closing Date the Company shall have performed all covenants and agreements of the Company contained herein or in any of the other Transaction
Documents required to be performed by the Company on or before the Closing Date; 
  
 (d) No event which, if the Note were outstanding, would constitute an Event of Default or Repurchase Event or which, with the giving of notice or the passage of time, or both, would constitute an Event of Default or
Repurchase Event shall have occurred and be continuing; 
  

 - 24 - 








 (e) The Company shall have delivered to the Purchaser a certificate, dated the Closing Date, duly
executed by its Chief Executive Officer or Chief Financial Officer, to the effect set forth in subparagraphs (a), (b), (c) and (d) of this Section 7.2; 
  
 (f) The Company shall have delivered to the Purchaser a certificate, dated the Closing Date, of the Secretary of the Company certifying (A) the Articles
of Incorporation and By-Laws of the Company as in effect on the Closing Date, (B) all resolutions of the Board of Directors (and committees thereof) of the Company relating to this Agreement and the other Transaction Documents and the transactions
contemplated hereby and thereby, (C) the due election or appointment, incumbency and specimen signature of each officer of the Company who executes any Transaction Document, with provisions for counter-certification of the election or appointment,
incumbency and signature of the Secretary of the Company by another officer of the Company; 
  
 (g) The Purchaser shall have received an opinion of Goodwin Procter LLP, counsel for the Company, dated the Closing Date, addressed to the Purchaser, substantially in the form attached as Exhibit D and
otherwise in form, scope and substance reasonably satisfactory to the Purchaser; 
  
 (h) The Purchaser shall have received an opinion of Woods Rogers PLC, counsel for the Company, dated the Closing Date, addressed to the Purchaser, substantially in the form attached as Exhibit E and otherwise
in form, scope and substance reasonably satisfactory to the Purchaser; 
  
 (i) The Company shall have received confirmation from Nasdaq, and provided the Purchaser reasonable evidence or if such confirmation is in written form, a copy thereof, that the transactions contemplated hereby will not require stockholder
approved pursuant to Rule 4350(i) of Nasdaq rules; and 
  
 (j) On
the Closing Date, (i) trading in securities on the NYSE, the AMEX or Nasdaq shall not have been suspended or materially limited and (ii) a general moratorium on commercial banking activities in the State of New York shall not have been declared by
either federal or state authorities, nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity or crisis of such magnitude in its effect on, or any material adverse change in any
United States financial market which, in each case, in the good faith judgment of the Purchaser, makes it impracticable or inadvisable to purchase the Note and Warrant. 
  
 8. Miscellaneous. 
  
 8.1 Successors and Assigns. This Agreement may not be assigned by the Company. This Agreement may not be assigned by the Purchaser prior to
the Closing without the prior written consent of the Company, which consent may not be unreasonably withheld or delayed. After the Closing, (1) without the prior written consent of the Company, but after notice given to the Company, the Purchaser
may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or an investment fund for which the investment 

  

 - 25 - 








 
advisor is the same as, or is an Affiliate of, the Purchaser’s investment advisor or (2) subject to and upon compliance with the assignment and transfer
provisions, if any, of the Securities, to any transferee of Securities from the Purchaser. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. 
  
 8.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 8.3 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 8.4 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given only upon delivery to each party to be notified by (i) personal delivery, (ii) telephone line facsimile transmission (such delivery shall be deemed to occur upon receipt of confirmation of complete transmittal), or (iii) a
recognized overnight air courier, addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other party (such delivery shall be deemed to
occur one day following the deposit with such overnight air courier): 
  
 If to the Company: 
  

			
	 Insmed Incorporated

	 4851 Lake Brook Drive

	 Glen Allen, Virginia 23060

		
	 Attention:
	  	Chief Financial Officer
		
	Telephone:	  	(804) 565-3000
	Fax:	  	(804) 565-3500

  
 If to the Purchaser:

  
 to the address set forth on the signature
pages hereto. 
  
 8.5 Expenses. The parties hereto
shall pay their own costs and expenses in connection herewith. The Company shall pay all fees and expenses of all finders, brokers, placement agents in connection with the transactions contemplated by this Agreement pursuant to any separate
agreement between one or more such parties and the Company. 
  

 - 26 - 








 8.6 Amendments and Waivers. 
  
 (a) No amendment, modification, waiver, discharge or termination of any provision of this Agreement on or prior to the
Closing Date nor consent to any departure by the Purchaser or the Company therefrom on or prior to the Closing Date shall in any event be effective unless the same shall be in writing and signed by the party to be charged with enforcement, and in
any such case shall be effective only in the specific instance and for the purpose for which given; 
  
 (b) No amendment, modification, waiver, discharge or termination of any provision of this Agreement after the Closing Date nor consent to any departure by
the Company therefrom after the Closing Date shall in any event be effective unless the same shall be in writing and signed (x) by the Company, if the Company is to be charged with enforcement or (y) by the Majority Holders, if the Purchaser is to
be charged with enforcement, and in any such case shall be effective only in the specific instance and for the purpose for which given; provided, however, that no such amendment modification, waiver, discharge or termination which (i)
increases the Purchaser’s liability, (ii) amends this Section 8.6, (iii) adversely affects the Purchaser’s rights under Sections 6.1, 6.2, 6.5, 6.6, 6.7, 6.8, 6.9, 6.10, 6.11, 6.14 and 6.15, (iv) modifies the provisions of this Agreement
in a manner that adversely treats the obligations or rights of the Purchaser differently than it treats the obligations or rights of the purchasers under the Other Purchase Agreements, or (v) decreases the Purchaser’s Restricted Ownership
Percentage, shall be effective unless in writing signed by the Purchaser; provided further, however, that any such amendment, modification, waiver, discharge or termination of a provision effected in accordance with this Section 8.6 shall be
binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all such securities, and the Company. Notwithstanding anything to the contrary contained herein, no amendment or waiver shall
increase or eliminate the Restricted Ownership Percentage, whether permanently or temporarily, unless, in addition to complying with the other requirements herein and obtaining the written consent of the Purchaser, such amendment or waiver shall
have been approved in accordance with the Virginia Stock Corporation Act and the Company’s by-laws by holders of a majority of the outstanding shares of Common Stock entitled to vote at a meeting or by written consent in lieu of such meeting.

  
 8.7 Severability. If one or more provisions of
this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms. 
  
 8.8 Entire Agreement.
This Agreement, including the Exhibits and Schedules hereto, the other Transaction Documents and other documents contemplated hereby and thereby constitute the entire agreement among the parties hereof with respect to the subject matter hereof and
thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof and there are no representations or warranties, written or oral, by either party in
connection with this Agreement except as set forth herein and therein. 
  

 - 27 - 








 8.9 Further Assurances. The parties shall execute and deliver all such further instruments
and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 
  
 8.10 Applicable Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of New York without regard to principles of conflicts of laws. 
  
 8.11 Remedies. 
  
 (a) The Purchaser shall be entitled to specific performance of the Company’s obligations under the Transaction Documents. 
  
 (b) The Company on the one hand and the Purchaser on the other hand shall
indemnify the other and hold it harmless from any loss, cost, expense or fees (including reasonable attorneys’ fees and expenses) arising out of any breach of any of its representations, warranties, covenants or agreements in any of the
Transaction Documents, or arising out of the enforcement of this Section 8.11. 
  
 8.12 Jurisdiction. The parties hereby agree that all actions or proceedings arising directly or indirectly from or in connection with this Agreement shall be litigated only in the Supreme Court of the
State of New York or the United States District Court for the Southern District of New York located in New York County, New York. The Company consents and submits to the jurisdiction and venue of the foregoing courts and consents that any process or
notice of motion or other application to either of said courts or a judge thereof may be served on the Company inside or outside the State of New York or the Southern District of New York (but with respect to any party hereto, such consent shall not
be deemed a general consent to jurisdiction and service for any third parties) by registered mail, return receipt requested, directed to the Company at its address provided in or pursuant to this Agreement (and service so made shall be deemed
complete three days after the same has been posted as aforesaid) or by personal service or in such other manner as may be permissible under the rules of said courts. The Company hereby waives any right to object to a proceeding in such courts based
on inconvenience of the forum and waives and right to a jury trial in connection with any litigation pursuant to this Agreement. 
  
 8.13 Survival. The respective representations, warranties, covenants and agreements of the Company and the Purchaser contained in this
Agreement and the documents delivered in connection with this Agreement shall survive the execution and delivery of this Agreement and the other Transaction Documents and the Closing and delivery of and payment for the Note and issuance of the
Warrant, and shall remain in full force and effect regardless of any investigation made by or on behalf of the Purchaser or any Person controlling or acting on behalf of the Purchaser or by the Company or any Person controlling or acting on behalf
of the Company. 
  

 - 28 - 








 8.14 Construction; Purchaser Status. The language used in this Agreement will be deemed to
be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. The Purchaser is not acting as part of a “group” (as that term is used in Section 13(d) of the
1934 Act) in negotiating and entering into this Agreement or purchasing the Note and the Warrant or acquiring, disposing of or voting any of the Underlying Shares or the Warrant Shares. The Company hereby confirms that it understands and agrees that
the Purchaser is not acting as part of any such group. 
  
 8.15 Acknowledgment. Each of the Company and the Purchaser understands that pursuant to a waiver agreement between the Company and Wells Fargo Securities, LLC, Goodwin Procter LLP represents both the Company and Wells Fargo
Securities, LLC in connection with the transactions contemplated by this Agreement. Goodwin Procter LLP has not acted as counsel to the Purchaser. Each of the parties hereto further acknowledges that each of the Wells Fargo Securities, LLC and C.E.
Unterberg Towbin, LLC is acting solely as a financial advisor and/or placement agent to the Company and has not provided advice, or made any representation, to any purchaser in connection with the transactions contemplated by this Agreement, and
that the role of either of Wells Fargo Securities, LLC or C.E. Unterberg Towbin, LLC in any due diligence is limited solely to assisting the Company in co-ordinating the work of the Company’s other professional advisors. 
  
 8.16 Certain Waivers. To the extent that the Purchaser is a
party to a Stock and Warrant Purchase Agreement with the Company dated November 5, 2004 (together with each other Stock and Warrant Purchase Agreement entered into by the Company dated November 5, 2004, the “Prior Purchase Agreements”) and
pursuant to Section 9 of the Prior Purchase Agreements, the undersigned Purchaser, individually, and, together with the other Purchasers who are parties to the Prior Purchase Agreements as the holders of at least a majority in interest of the Shares
(as defined in the Prior Purchase Agreements) held by all of the parties to the Prior Purchase Agreements (the “Prior Purchasers”), hereby permanently and irrevocably waives on behalf of such Purchaser and all of the Prior Purchasers any
and all rights of first refusal granted pursuant to Section 7.8 of the Prior Purchase Agreements, any other provision of the Prior Purchase Agreements or any other agreement, any other rights to purchase any of the Securities of the Company being
sold pursuant to this Agreement and the Other Purchase Agreements and any rights to receive notice pursuant to such rights of first refusal or in connection with such sales of Securities, other than to the extent such rights are being exercised in
connection with the purchase of Securities pursuant to this Agreement or any Other Purchase Agreement. The Purchaser acknowledges that it has a right to participate in future sales by the Company of any of the Company’s securities in certain
capital raising transactions in accordance with the terms and conditions of Section 6 of this Agreement and hereby further agrees to permanently and irrevocably waive and terminate its rights to purchase securities pursuant to Section 7.8 of such
Purchaser’s Prior Purchase Agreement in the event of any future issuance of securities by the Company that would otherwise be subject to the requirements of such Section 7.8. 
  
 [Signature Pages Follow] 
  

 - 29 - 








 IN WITNESS WHEREOF, the parties have caused this Purchase Agreement to be duly executed by their
respective officers or other representatives thereunto duly authorized as of the date first above written. 
  

					
	INSMED INCORPORATED
		
	 By:
	 	 
	 	 	 Name:
	 	 Kevin P. Tully

	 	 	 Title:
	 	 Chief Financial Officer



  

 - 30 - 








 PURCHASER AGREEMENT SIGNATURE PAGE 
  

			
	
	 
	[Name of Purchaser]


  

					
		
	 By:
	 	 



					
	 	 	 Name:
	 	 
	 	 	 Title:
	 	 
		
	 Tax ID No.:
	 	 



					
		
	 Contact name:
	 	 



					
		
	 Telephone:
	 	 


  

			
	 Name in which shares should be registered (if
 different from name of Purchaser):

	
	 


  

			
	Address for Notices:
	
	 
	
	 



			
	
	Purchaser’s Residence:
	
	 



			
	
	FACSIMILE NUMBER:
	
	 


  

 - 31 - 








 PURCHASER INFORMATION 
  
 Purchaser Name: 
 Purchase Price: 
 Number of Warrant Shares: 
 Initial Conversion Price of Note: 
 Initial Exercise Price of Warrant: 
  

 - 32 -